Development of a novel multi‑epitope vaccine against the pathogenic human polyomavirus V6/7 using reverse vaccinology

Table 8 Analysis of MHC restriction data for worldwide population coverage

Population/Area	MHC I			MHC II			MHC I and MHC II Combined
Population/Area	Coverage(%)^a	Average hit^b	PC90^c	Coverage(%)^a	Average hit^b	PC90^c	Coverage(%)^a	Average hit^b	PC90^c
World	97.74%	3.2	1.55	26.99%	0.34	0.14	98.35%	3.54	1.77
East Asia	96.82%	3.29	1.62	53.39%	0.66	0.21	96.82%	3.29	1.62
Northeast Asia	91.63%	2.34	1.06	33.41%	0.39	0.15	91.63%	2.34	1.06
South Asia	88.69%	1.96	0.88	24.5%	0.29	0.13	88.69%	1.96	0.88
Southeast Asia	94.27%	3.05	1.26	41.54%	0.46	0.17	94.27%	3.05	1.26
Southwest Asia	89.37%	2.16	0.94	18.19%	0.21	0.12	89.37%	2.16	0.94
Europe	99.55%	3.86	2.18	20.76%	0.28	0.13	99.55%	3.86	2.18
East Africa	88.85%	2.18	0.9	28.6%	0.39	0.14	88.85%	2.18	0.9
West Africa	92.69%	2.38	1.11	52.54%	0.66	0.21	92.69%	2.38	1.11
Central Africa	84.65%	1.94	0.65	24.28%	0.35	0.13	84.65%	1.94	0.65
North Africa	92.84%	2.38	1.11	37.7%	0.51	0.16	92.84%	2.38	1.11
South Africa	91.08%	2.16	1.04	1.79%	0.02	0.1	91.08%	2.16	1.04
West Indies	98.25%	3.4	1.77	27.52%	0.37	0.14	98.25%	3.4	1.77
North America	98.19%	3.37	1.7	24.95%	0.32	0.13	98.19%	3.37	1.7
Central America	9.07%	0.14	0.11	16.53%	0.2	0.12	9.07%	0.14	0.11
South America	80.56%	2.05	0.51	27.31%	0.35	0.14	80.56%	2.05	0.51
Oceania	95.27%	3.08	1.35	35.77%	0.4	0.16	95.27%	3.08	1.35

^aProjected population coverage
^bAverage number of epitope hits/HLA combinations recognized by the population
^cMinimum number of epitope hits/HLA combinations recognized by 90% of the population

ISSN: 1471-2334